Topamax and Device occlusion - a phase IV clinical study of FDA data

Summary:

Device occlusion is reported as a side effect among people who take Topamax (topiramate), especially for people who are female, 60+ old, also take Diclofenac Potassium, and have Depression.

The phase IV clinical study analyzes which people have Device occlusion when taking Topamax. It is created by eHealthMe based on reports of 54,158 people who have side effects when taking Topamax from the FDA, and is updated regularly.

What is Topamax?

Topamax has active ingredients of topiramate. It is often used in migraine. eHealthMe is studying from 58,956 Topamax users. Check the latest studies of Topamax.

What is Device occlusion?

Device occlusion is found to be associated with 591 drugs and 514 conditions by eHealthMe. Check the latest studies of Device occlusion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

54,158 people reported to have side effects when taking Topamax.
Among them, 32 people (0.06%) have Device occlusion.

Among these 32 people:

What is the gender of people who have Device occlusion when taking Topamax? *

female: 94.12 %
male: 5.88 %

What is the age of people who have Device occlusion when taking Topamax? *

What are other drugs people take besides Topamax? *

What are other side effects people have besides Device occlusion? *

Headache (pain in head): 19 people, 59.38%
Weight Increased: 18 people, 56.25%
Tooth Abscess (pus formation in tooth): 18 people, 56.25%
High Blood Pressure: 18 people, 56.25%
Tooth Disorder (tooth disease): 17 people, 53.12%
Nausea (feeling of having an urge to vomit): 15 people, 46.88%
Dehydration (dryness resulting from the removal of water): 14 people, 43.75%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 14 people, 43.75%
Memory Loss: 14 people, 43.75%
Hyperlipidaemia (presence of excess lipids in the blood): 14 people, 43.75%

What are the existing conditions these people have? *

Sleep Disorder: 14 people, 43.75%
Nausea (feeling of having an urge to vomit): 14 people, 43.75%
Depression: 14 people, 43.75%
Muscle Spasms (muscle contraction): 13 people, 40.62%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 13 people, 40.62%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 13 people, 40.62%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 6 people, 18.75%
Immunodeficiency Common Variable: 6 people, 18.75%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 1 person, 3.12%
Schizoaffective Disorder (a mental disorder characterized by disordered thought): 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Topamax and have Device occlusion?

- Check whether Device occlusion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Topamax:

Topamax (58,956 reports)

Device occlusion treatments and more:

Device occlusion (13,307 reports)

Browse all side effects of Topamax:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Device occlusion:

Device occlusion (591 drugs)

Browse all the conditions that are associated with Device occlusion:

Device occlusion (514 conditions)

Related publications that referenced our studies

Baloch M, Siddiqui MA, "Topiramate induced sudden loss of vision", JPMA, 2012 Oct .
Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .
Baloch M, Siddiqui MA, "Topiramate induced sudden loss of vision", JPMA, 2012 Oct .
Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on topiramate (the active ingredients of Topamax) and Topamax (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.